CV Sciences, Inc. (CVSI): Cost of Revenue
$7.04M
Year ended 2025-12-31
$6.48M
Trailing 12 months to 2026-06-30
-12.9%
3-year compound annual growth
-12.1%
5-year compound annual growth
+3.9%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.04M | -17.6% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $8.54M | -4.3% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $8.92M | -16.3% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $10.65M | -6.8% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $11.43M | -14.8% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $13.42M | -27.9% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $18.61M | +29.5% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $14.37M | +132.1% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $6.19M | +52.4% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $4.06M | -15.3% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $4.80M | n/c | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $4.39M | +398.3% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $880.5K | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $2.39M | +402.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
| uniQure N.V. (QURE) | 2025-12-31 | $1.69M | +33.1% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $3.77M | +93.0% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $4.62M | +20.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $10.64M | -38.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.03M | +7.1% |
Compare CVSI, PYXS, TNXP, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗